1
|
Interleukin-10-secreting type 1 regulatory T cells in rodents and humans.
|
Immunol Rev
|
2006
|
6.08
|
2
|
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans.
|
Nat Rev Immunol
|
2007
|
4.55
|
3
|
Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells.
|
J Exp Med
|
2002
|
3.49
|
4
|
Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner.
|
Immunity
|
2011
|
3.38
|
5
|
Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway.
|
Blood
|
2010
|
2.15
|
6
|
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
|
Blood
|
2011
|
2.12
|
7
|
WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells.
|
J Exp Med
|
2007
|
1.77
|
8
|
A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome.
|
J Clin Invest
|
2007
|
1.67
|
9
|
STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells.
|
Int Immunol
|
2008
|
1.58
|
10
|
Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice.
|
Blood
|
2003
|
1.56
|
11
|
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells.
|
Diabetes
|
2008
|
1.49
|
12
|
Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
|
Diabetes
|
2009
|
1.48
|
13
|
Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation.
|
Transplantation
|
2015
|
1.44
|
14
|
Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes.
|
Diabetes
|
2011
|
1.39
|
15
|
Comment on M. Guillot-Delost et al. (2008;10:834-846): Clinical-grade preparation of human natural regulatory T cells encoding the thymidine kinase suicide gene as a safety gene.
|
J Gene Med
|
2009
|
1.39
|
16
|
Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells.
|
Haematologica
|
2011
|
1.20
|
17
|
Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.
|
Diabetes
|
2009
|
1.18
|
18
|
Reduction of circulating neutrophils precedes and accompanies type 1 diabetes.
|
Diabetes
|
2013
|
1.17
|
19
|
Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications.
|
Curr Top Microbiol Immunol
|
2014
|
1.13
|
20
|
Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.
|
J Neuroimmunol
|
2010
|
1.08
|
21
|
Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant.
|
Diabetes
|
2009
|
1.08
|
22
|
Platelet factor 4 differentially modulates CD4+CD25+ (regulatory) versus CD4+CD25- (nonregulatory) T cells.
|
J Immunol
|
2005
|
1.06
|
23
|
Calcineurin inhibitor-free immunosuppressive regimen in type 1 diabetes patients receiving islet transplantation: single-group phase 1/2 trial.
|
Transplantation
|
2014
|
1.01
|
24
|
The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells.
|
Blood
|
2007
|
0.93
|
25
|
Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation.
|
PLoS One
|
2011
|
0.91
|
26
|
The role of interleukin 10 in the control of autoimmunity.
|
J Autoimmun
|
2003
|
0.89
|
27
|
Modulation of early inflammatory reactions to promote engraftment and function of transplanted pancreatic islets in autoimmune diabetes.
|
Adv Exp Med Biol
|
2010
|
0.89
|
28
|
Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity.
|
Clin Immunol
|
2013
|
0.89
|
29
|
Abnormalities of the Exocrine Pancreas in Type 1 Diabetes.
|
Curr Diab Rep
|
2015
|
0.87
|
30
|
Allogeneic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice.
|
Exp Cell Res
|
2006
|
0.87
|
31
|
Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice.
|
PLoS One
|
2010
|
0.83
|
32
|
Relevance of hyperglycemia on the timing of functional loss of allogeneic islet transplants: implication for mouse model.
|
Transplantation
|
2007
|
0.83
|
33
|
Lack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice.
|
Diabetologia
|
2015
|
0.82
|
34
|
Re-establishing immune tolerance in type 1 diabetes via regulatory T cells.
|
Novartis Found Symp
|
2008
|
0.80
|
35
|
Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy?
|
Immunol Lett
|
2009
|
0.78
|
36
|
Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation.
|
Curr Opin Hematol
|
2005
|
0.77
|
37
|
Standardization in flow cytometry: correct sample handling as a priority.
|
Nat Rev Immunol
|
2012
|
0.75
|
38
|
All in (IL-) 1?
|
Transplantation
|
2015
|
0.75
|